Randomized phase-II evaluation of letrozole plus dasatinib in hormone receptor positive metastatic breast cancer patients

Devchand Paul; Svetislava J. Vukelja; Frankie Ann Holmes; Joanne L. Blum; Kristi J. McIntyre; Deborah L. Lindquist; Cynthia R. Osborne; Ines J. Sanchez; Jerome H. Goldschmidt; Yunfei Wang; Lina Asmar; Lewis Strauss; Joyce O’Shaughnessy

doi:10.1038/S41523-019-0132-8

Randomized phase-II evaluation of letrozole plus dasatinib in hormone receptor positive metastatic breast cancer patients

Devchand Paul
, Svetislava J. Vukelja
, Frankie Ann Holmes
, Joanne L. Blum
, Kristi J. McIntyre
, Deborah L. Lindquist
, Cynthia R. Osborne
, Ines J. Sanchez
, Jerome H. Goldschmidt
, Yunfei Wang
, Lina Asmar
, Lewis Strauss
, Joyce O’Shaughnessy

US Oncology Research, Inc., The Woodlands, USA
Texas Oncology
Baylor University Medical Center
NewYork–Presbyterian Hospital
1US Oncology Research, Inc., 10101 Woodloch Forest Dr., The Woodlands, TX 77380 USA.
Bristol-Myers Squibb

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	NPJ breast cancer
Volume	5
Issue number	1
DOIs	https://doi.org/10.1038/S41523-019-0132-8
State	Published - Oct 28 2019
Externally published	Yes

Disciplines

Medicine and Health Sciences
Oncology
Internal Medicine

Access to Document

10.1038/S41523-019-0132-8License: Unspecified

Cite this

Paul, D., Vukelja, S. J., Holmes, F. A., Blum, J. L., McIntyre, K. J., Lindquist, D. L., Osborne, C. R., Sanchez, I. J., Goldschmidt, J. H., Wang, Y., Asmar, L., Strauss, L., & O’Shaughnessy, J. (2019). Randomized phase-II evaluation of letrozole plus dasatinib in hormone receptor positive metastatic breast cancer patients. NPJ breast cancer, 5(1). https://doi.org/10.1038/S41523-019-0132-8

Paul, D, Vukelja, SJ, Holmes, FA, Blum, JL, McIntyre, KJ, Lindquist, DL, Osborne, CR, Sanchez, IJ, Goldschmidt, JH, Wang, Y, Asmar, L, Strauss, L & O’Shaughnessy, J 2019, 'Randomized phase-II evaluation of letrozole plus dasatinib in hormone receptor positive metastatic breast cancer patients', NPJ breast cancer, vol. 5, no. 1. https://doi.org/10.1038/S41523-019-0132-8

@article{fa610415b3f54b3f81a0c253102cfe37,

title = "Randomized phase-II evaluation of letrozole plus dasatinib in hormone receptor positive metastatic breast cancer patients",

author = "Devchand Paul and Vukelja, \{Svetislava J.\} and Holmes, \{Frankie Ann\} and Blum, \{Joanne L.\} and McIntyre, \{Kristi J.\} and Lindquist, \{Deborah L.\} and Osborne, \{Cynthia R.\} and Sanchez, \{Ines J.\} and Goldschmidt, \{Jerome H.\} and Yunfei Wang and Lina Asmar and Lewis Strauss and Joyce O{\textquoteright}Shaughnessy",

note = "The non-receptor tyrosine kinase Src activation plays a role in the malignant progression of breast cancer, including development of endocrine therapy resistance and survival of bone metastases. This study investigated whether adding Src kinase inhibitor dasatinib to aromatase inhibitor (AI) therapy improved outcomes in estrogen receptor (ER)-positive, HER2-negative metastatic breast cancer (MBC).",

year = "2019",

month = oct,

day = "28",

doi = "10.1038/S41523-019-0132-8",

language = "American English",

volume = "5",

journal = "NPJ breast cancer",

number = "1",

}

TY - JOUR

T1 - Randomized phase-II evaluation of letrozole plus dasatinib in hormone receptor positive metastatic breast cancer patients

AU - Paul, Devchand

AU - Vukelja, Svetislava J.

AU - Holmes, Frankie Ann

AU - Blum, Joanne L.

AU - McIntyre, Kristi J.

AU - Lindquist, Deborah L.

AU - Osborne, Cynthia R.

AU - Sanchez, Ines J.

AU - Goldschmidt, Jerome H.

AU - Wang, Yunfei

AU - Asmar, Lina

AU - Strauss, Lewis

AU - O’Shaughnessy, Joyce

N1 - The non-receptor tyrosine kinase Src activation plays a role in the malignant progression of breast cancer, including development of endocrine therapy resistance and survival of bone metastases. This study investigated whether adding Src kinase inhibitor dasatinib to aromatase inhibitor (AI) therapy improved outcomes in estrogen receptor (ER)-positive, HER2-negative metastatic breast cancer (MBC).

PY - 2019/10/28

Y1 - 2019/10/28

UR - http://www.nature.com/articles/s41523-019-0132-8

U2 - 10.1038/S41523-019-0132-8

DO - 10.1038/S41523-019-0132-8

M3 - Article

VL - 5

JO - NPJ breast cancer

JF - NPJ breast cancer

IS - 1

ER -

Randomized phase-II evaluation of letrozole plus dasatinib in hormone receptor positive metastatic breast cancer patients

Disciplines

Access to Document

Other files and links

Cite this